Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruitao Lin

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Statistics in Medicine|May 15, 2024
Design and sample size determination for multiple-dose randomized phase II trials for dose optimizationPeng Yang, Daniel Li, Ruitao Lin, et al.
JCO Precision Oncology|December 7, 2020
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted TherapiesRuitao Lin, Yanhong Zhou, Fangrong Yan, et al.
Statistics in Medicine|June 10, 2024
REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priorsCheng-Han Yang, Evan Kwiatkowski, J Jack Lee, et al.
Statistics in Medicine|April 11, 2025
A Generalized Phase I/II Dose Optimization Trial Design With Multi-Categorical and Multi-Graded OutcomesYichen Yan, Ruitao Lin, Tianyu Guan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2018
Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I TrialsYing Yuan, Ruitao Lin, Daniel Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Generalised pairwise comparisons in dose-optimisation oncology trials: beyond safety to multi-outcome dose selectionEmily Alger, Ruitao Lin, J Jack Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Practical Considerations for Using the TITE-BOIN Design to Handle Late-onset Toxicity or Fast Accrual in Phase I TrialsKai Chen, Ting-Yu Chen, Yiming Zhang, et al.
Statistics in Medicine|December 3, 2025
Bayesian Integrated Learning of Longitudinal Dose-Response Relationships via Decentralized Clinical TrialsJingyi Zhang, Tuo Wang, Yongming Qu, et al.
JCO Precision Oncology|August 29, 2024
Pharmacodynamic Activity of [<sup>18</sup>F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With <i>BRCA1/2</i>-Mutated Breast Cancer Receiving TalazoparibLilie L Lin, Franklin Wong, Ruitao Lin, et al.
JCO Clinical Cancer Informatics|January 13, 2021
BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical TrialsYanhong Zhou, Ruitao Lin, Ying-Wei Kuo, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Statistics in Medicine|May 15, 2024
Design and sample size determination for multiple-dose randomized phase II trials for dose optimizationPeng Yang, Daniel Li, Ruitao Lin, et al.
JCO Precision Oncology|December 7, 2020
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted TherapiesRuitao Lin, Yanhong Zhou, Fangrong Yan, et al.
Statistics in Medicine|June 10, 2024
REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priorsCheng-Han Yang, Evan Kwiatkowski, J Jack Lee, et al.
Statistics in Medicine|April 11, 2025
A Generalized Phase I/II Dose Optimization Trial Design With Multi-Categorical and Multi-Graded OutcomesYichen Yan, Ruitao Lin, Tianyu Guan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2018
Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I TrialsYing Yuan, Ruitao Lin, Daniel Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Generalised pairwise comparisons in dose-optimisation oncology trials: beyond safety to multi-outcome dose selectionEmily Alger, Ruitao Lin, J Jack Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Practical Considerations for Using the TITE-BOIN Design to Handle Late-onset Toxicity or Fast Accrual in Phase I TrialsKai Chen, Ting-Yu Chen, Yiming Zhang, et al.
Statistics in Medicine|December 3, 2025
Bayesian Integrated Learning of Longitudinal Dose-Response Relationships via Decentralized Clinical TrialsJingyi Zhang, Tuo Wang, Yongming Qu, et al.
JCO Precision Oncology|August 29, 2024
Pharmacodynamic Activity of [<sup>18</sup>F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With <i>BRCA1/2</i>-Mutated Breast Cancer Receiving TalazoparibLilie L Lin, Franklin Wong, Ruitao Lin, et al.
JCO Clinical Cancer Informatics|January 13, 2021
BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical TrialsYanhong Zhou, Ruitao Lin, Ying-Wei Kuo, et al.
Pageof 10